CA-CAREISMATIC-BRANDS
24.9.2020 15:02:11 CEST | Business Wire | Press release
Careismatic Brands, the world’s largest designer and manufacturer of medical apparel, today announced the launch of a global tribute and charitable fundraising campaign, “19 Days of Gratitude,” spotlighting the heroism of nurses as they continue to battle COVID-19 on the front lines. Launching in a year that the World Health Organization has deemed “The International Year of The Nurse and Midwife,” and timed to the 200th anniversary of Florence Nightingale’s birth, the new campaign will celebrate nurses by revealing 19 stories that showcase frontline nurses from around the world over 19 consecutive days. The campaign will debut on careismatic.com/TributeToCourage and across Careismatic’s various social and digital channels, to celebrate the nursing community and raise money for the DAISY (Diseases Attacking the Immune System) Foundation, a worldwide organization recognizing the incredible work and sacrifice of nurses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005263/en/
The campaign will kick off with a powerful tribute video “In The Year of The Nurse – A Tribute to Courage,” shot and produced by Hollywood creative agency Mob Scene . The video features a reimagined recording of George Harrison’s classic song, “Give Me Love (Give Me Peace on Earth)” from Grammy Award-winning music producer Rob Cavallo (former Chairman of Warner Bros. Records, whose accolades include 1988 Producer of the Year; 2005 Record of the Year for Green Day’s Boulevard of Broken Dreams ; and selling in excess of 160 million records worldwide). Cavallo’s version of “Give Me Love (Give Me Peace on Earth)” features children singing from home and is designed to recognize and uplift health care professionals during this pandemic.
“Health care professionals are selfless people who are putting themselves on the line to save people’s lives during this COVID-19 crisis and this campaign is a tribute to them,” said Michael Singer, CEO of Careismatic Brands. “Our mission at Careismatic Brands is to champion the people behind the scrubs, and we are honored to share this very meaningful tribute as a way to thank the people who have given so much hope and professional care – at much personal risk – to so many COVID patients during these extraordinary times.”
Cavallo rerecorded the song during the middle of the pandemic’s stay-at-home mandate, so he was forced to creatively develop a process of overlaying each individual singer’s track while working remotely with engineers and musicians.
“We kept coming back to Give Me Love’s lyrics, which are incredibly meaningful and exactly what people need to hear during these unprecedented times,” Cavallo said. “George Harrison found the song to be profoundly moving and described it as a prayer and personal statement between him, the Lord and whoever likes it. If our version of this beautiful classic can brighten one nurse’s day after the incredible sacrifice they are making, it is all worth it.”
The video ends by encouraging viewers to donate to the DAISY Foundation. The fundraising effort will support their traditional programs as well as a new initiative awarding nurses grants to advance health equity in underserved communities.
“Careismatic Brands has been a longtime supporter of the DAISY Foundation and our mission to award and celebrate nurses as the unsung heroes providing quality health care,” said Bonnie Barnes, Co-Founder of the DAISY Foundation. “When we first saw the ‘Tribute to Courage’ video and heard its score with the plea for love and hope, we were immediately struck by its power and ability to provide a much-needed lift to nurses during this incredibly difficult time. We are thrilled that Careismatic Brands will be bringing this important tribute to nurses and offering a fundraising opportunity to the public,” Barnes continued. “Donations will fund nurse recognition as well as important research done by nurses to ensure that all people, no matter their race or economic situation, receive high-quality health care.”
Careismatic Brands’ “19 Days of Gratitude” campaign comes on the heels of the company’s $1 million donation of its Cherokee Uniforms and Dickies Medical branded scrubs to health care workers. The company delivered scrubs to more than 200 hospitals, in areas most impacted by the virus, to help health care workers lacking personal protective equipment get the apparel they needed to either change or even dispose of their scrubs throughout the day to avoid viral spread.
For more information on how to access the campaign, music video, 19 stories from nurses around the globe and to donate, please visit careismatic.com/TributeToCourage .
ABOUT CAREISMATIC BRANDS
Careismatic Brands, Inc. (formerly Strategic Partners, Inc.) is the global leader in medical apparel with a distribution footprint in more than 70 countries, and a deep portfolio of top-selling medical apparel, footwear and accessories brands such as Cherokee Uniforms, Dickies Medical, heartsoul, Infinity by Cherokee, ScrubStar, Tooniforms and Anywear. Plus innovative and game-changing wellbeing brands such as Certainty SmartBoost, an antimicrobial laundry additive that works alongside regular detergent to protect fabrics. Careismatic Brands’ portfolio of deeply trusted brands delivers best-in-class products and unparalleled service to distribution partners and consumers.
In addition to being the marketshare leader in medical apparel, Careismatic Brands is a manufacturer/distributor of school uniforms by Classroom, corporate identity uniforms, adaptive clothing by Silverts, medical instruments and accessories. The company takes great care to understand and provide products that champion the people wearing uniforms who serve and care for others. For more information on Careismatic Brands, visit www.careismatic.com and follow us on Facebook and Instagram .
ABOUT DAISY
The DAISY Foundation™ is the leading international organization for nursing recognition. It was created in 1999 by the family of J. Patrick Barnes, in memory of the extraordinary nursing care they experienced when he was in the hospital for 2 months with an auto-immune disease. (DAISY stands for D iseases A ttacking the I mmune SY stem). His family’s drive to say “thank you” to nurses for the compassionate and skillful care they provide every day – The DAISY Award® for Extraordinary Nurses – has grown to become a highly respected and international nurse recognition program. It provides unique and meaningful recognition that benefits nurses and the organizations where they work.
Today, over 4,500 healthcare organizations and schools of nursing in 29 countries are committed to honoring their nurses with The DAISY Award. Over 1.8 million nurses have been nominated by their patients, families and colleagues, and over 144,000 awards have been granted.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
